NCT01445067View on ClinicalTrials.gov

Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Migraine
Interventions
DRUG

BMS-927711 (CGRP Antagonist)

Capsule, Oral, 300 mg, Once, One day

DRUG

BMS-927711 (CGRP Antagonist)

Capsule, Oral, 600 mg, Once, One day

Trial Locations (4)

32806

Compass Research, Llc, Orlando

45255

Community Research, Cincinnati

90806

Collaborative Neuroscience Network, Inc., Long Beach

91206

California Clinical Trials Medical Group, Glendale

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01445067 - Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition | Biotech Hunter | Biotech Hunter